
### Introduction To Phased RF Technology Dr Khalameizer Vladimir, Barzilay MC January 2013






#### **Lesion Creation – Accurate Temp Control**

Temperature driven system with a maximum power limit (10W)



- Anatomically designed catheters
  - Allow accurate measurement of electrode-tissue interface temperature



- Electrode Cooling
  - Finned Electrodes to cool without irrigation
  - Duty-cycled power delivery cooling during "off" periods

#### **Lesion Creation**

- Temperature-Controlled
- Electrode Cooling
- Low Power
- Five Energy modes


40 50 60 70 80 90 100

- Energy Delivery
  - Phased RF Delivery
  - Energy Delivery Fields
  - Duty Cycles




#### **Lesion Creation – Accurate Temp Control**

- Multiple small electrodes in an array
  - Mitigates thermal gradients, 'hotspots', overheating seen with single large electrodes
  - Power output is adjusted at each electrode to achieve target temperature






# How can small electrodes with 10W max power create a deep contiguous lesion?




#### **Lesion Creation – Five Energy Modes**

- Five different energy modes
  - Unipolar Only
  - 1:1 (50% bipolar, 50% unipolar)
  - 2:1 (66% bipolar, 33% unipolar)
  - 4:1 (80% bipolar, 20% unipolar)
  - Bipolar Only
- Modes allow user to control lesion depth and fill







MAAC  $60^{\circ}$  C – 60s Energy Mode: <u>1:1</u>

Lesion forms ~50 $^{\circ}~$  C Tissue Discoloration ~60 $^{\circ}~$  C <sup>1</sup>


<sup>1</sup>D. Panescu, J. Whayne, S. Fleischman, M. Mirotznik, D. Swanson, J. Webster, "Three-dimensional finite even ont analysis of current density and temperature distributions giving radio-frequency appellation," *IEEE Trans Biomed Eng*, Vol. 42, No. 9, p.879-890, Sep. 1995.





#### **Lesion Creation – Five Energy Modes**


In-vitro Lesion Characterization: MAAC


 Lesion Depth Decrease from Unipolar → Bipolar






























## **PV SIGNALS**






## PV potential during pacing from distal CS (pre ablation)




for

## No PV signals during pacing from distal CS (post ablation)






#### PV signals during SR (pre ablation)



for




## PV – LA signals dissociation (post ablation)




for

### PV Isolation - **Exit** Block (pacing from the vein)



Bo


## **AF Termination During Ablation**



by

\*\* \*\* \*

## **AF Termination During Ablation**








## **AF Termination During Ablation**

t+



## AF Classification:

- Patients total 70
- Paroxysmal AF 51 72.8%
- Persistent AF 16 22.8 %
- Long Standing AF 3 4.3%





### **Success Rate:**

- Patients (N) 70
- No. of procedures 74 (Redo 4 procedures)
- Parox. AF Success rate 83 %
- Persistent AF Success rate 60%
- Long Standing AF Success rate- 1 patient after one year in SR without AAD, 1 patient in SR with amiodarone, 1 patient still in AF.

## **Procedure Data:**

- Procedure duration (skin to skin) 75+-15 (min)
- X-ray (min) 20+-5 (min)




## **Complications:**

- Pseudo Aneurysm 2 Patients
- No Perforation
- No Tamponade
- No Stroke







Simple procedural changes reduced the ACE rate with PVAC to 1.7%

No observable change in baseline, post-ablation and 1-month neurological scores (MMSE and NIHSS)

#### Acute Safety and Effectiveness

#### Acute Safety Events

 1.7% (1/60) major complications were reported (groin hematoma requiring intervention)

#### Acute Effectiveness

- 100% (240/240) of targeted veins were acutely isolated per investigator protocol
- Disabling PVAC electrode 1 or 10 did not impact the number of RF applications per subject from previously published values (28.8 +/- 16.1)<sup>44</sup>



#### **Procedural Mitigations to Reduce Embolic Load**

E1:10 Interaction<sup>27</sup>

- Disable Pair 1 or Pair 5 prior to ablation
- Electrode Contact Management<sup>28</sup>
  - Disable electrode pairs with ineffective contact
  - Avoid repositioning the catheter during ablation
  - Pull catheter away from endocardium to reposition
- Sheath Management<sup>55</sup>
  - Submerged catheter loading
  - Deliberate insertion and withdrawal of the catheter
- Anticoagulation<sup>53,55</sup>
  - Continuous anticoagulation (INR>2)
  - ACT > 350s

